While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
Novo Nordisk (NVO) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.
Pharmaceutical group Shire (SHP.L) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche (ROG.S) over its hemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment. Swiss drugmaker Roche is hoping to win a slice of the $11 billion-a-year hemophilia drug market with emicizumab, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk (NOVOb.CO) and Shire.
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk
Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.
All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.
Top Analyst Reports for Caterpillar, Intel & Monsanto
Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.
Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.